Treosulfan and Fludarabine Pre-Transplant

An Open-label, Non-randomized, Prospective Trial to Evaluate the Effect of Renal Function Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics in Patients With AML or MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
36 patients (estimated)
Sponsors
medac GmbH
Collaborators
Synteract, Inc.
Tags
Antimetabolites, Chemotherapy, Pre-Allogeneic Stem Cell Transplant
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1847
NCT Identifier
NCT05534620

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.